

Development of Microfluidic Platforms for Organoid Growth and Vascularization

Favour Olaoye and Kaledio Potter

EasyChair preprints are intended for rapid dissemination of research results and are integrated with the rest of EasyChair.

March 4, 2024

Development of Microfluidic Platforms for Organoid Growth and Vascularization

Date: 12 Feb, 2024

Authors Favour Olaoye, Kaledio Potter

Abstract:

Organoids, three-dimensional (3D) structures that recapitulate the architecture and functionality of organs, hold great promise for disease modeling, drug discovery, and regenerative medicine. However, the successful translation of organoids into clinical applications requires the development of robust and physiologically relevant culture systems that can support their growth, maturation, and vascularization. Microfluidic platforms have emerged as powerful tools for achieving these goals due to their ability to precisely control the cellular microenvironment, mimic physiological conditions, and facilitate the integration of vascular networks.

This abstract highlights recent advancements in the development of microfluidic platforms specifically designed for organoid growth and vascularization. Firstly, it discusses the importance of recapitulating the native tissue microenvironment, including appropriate mechanical cues, oxygen gradients, nutrient supply, and waste removal. Microfluidic systems offer precise control over these parameters, allowing for the customization of culture conditions to enhance the growth and functionality of organoids.

Secondly, the abstract presents strategies for integrating vascular networks within organoids using microfluidic platforms. Vascularization is crucial for maintaining the viability of larger and more complex organoids by enabling efficient nutrient and oxygen delivery, as well as waste removal. Several approaches have been explored, including the incorporation of endothelial cells, perfusable microchannels, and biomimetic scaffolds within the microfluidic devices. These strategies promote the formation of functional blood vessels and enhance the maturation and longevity of organoids.

Furthermore, the abstract discusses the utilization of microfluidic platforms for studying disease mechanisms and drug responses in organoids. By incorporating patient-derived cells or gene editing techniques, microfluidic organoid models can be tailored to specific diseases, providing a more accurate representation of human physiology compared to traditional two-dimensional cell cultures. This enables the investigation of disease progression, identification of novel therapeutic targets, and evaluation of drug efficacy in a high-throughput manner.

Lastly, the abstract highlights the challenges and future directions in the field of microfluidic organoid culture. These include the need for standardization of culture protocols, scalability of microfluidic systems, integration of multiple organoid types, and long-term functionality of vascular networks. Addressing these challenges will facilitate the translation of microfluidic platforms into clinical applications, such as personalized medicine and tissue engineering.

Introduction:

Organoids, three-dimensional (3D) structures that mimic the architecture and functionality of organs, have emerged as powerful tools in various fields, including disease modeling, drug screening, and regenerative medicine. They offer the potential to bridge the gap between traditional two-dimensional cell cultures and complex human tissues, providing a more accurate representation of human physiology and pathology. However, the successful translation of organoids into clinical applications requires the development of robust and physiologically relevant culture systems that can support their growth, maturation, and vascularization.

Historically, organoids have been cultured using conventional methods, such as suspension cultures, scaffold-based systems, or embedding in extracellular matrices. While these methods have contributed to significant advancements, they often fail to fully recapitulate the native tissue microenvironment, resulting in limited functionality and scalability. Furthermore, the lack of vascularization within organoids poses a challenge, as it restricts nutrient and oxygen supply, leading to limited growth and compromised functionality in larger and more complex structures.

Microfluidic platforms have emerged as a promising solution to address these limitations. These platforms leverage the principles of microscale fluid dynamics and offer precise control over the cellular microenvironment, allowing for the simulation of complex physiological conditions. Microfluidic systems enable the manipulation of factors such as flow rates, oxygen gradients, nutrient supply, and waste removal, providing a more physiologically relevant culture environment for organoids.

One of the key advantages of microfluidic platforms is their ability to integrate vascular networks within organoids. Vascularization is a critical aspect of organoid culture as it enables efficient nutrient and oxygen exchange, waste removal, and the establishment of functional tissue interfaces. Microfluidic devices can be designed to incorporate perfusable microchannels, endothelial cells, or biomimetic scaffolds, enabling the formation of functional blood vessels within organoids. This vascular network integration enhances the viability, maturation, and functionality of organoids, making them more representative of native tissues.

Moreover, microfluidic platforms offer a platform for studying disease mechanisms and drug responses in organoids. By incorporating patient-derived cells or utilizing gene editing techniques, microfluidic organoid models can be tailored to specific diseases, allowing for the investigation of disease progression, identification of novel therapeutic targets, and evaluation of drug efficacy. The ability to perform high-throughput screening on microfluidic platforms further accelerates drug discovery and personalized medicine efforts.

Despite the significant advancements in microfluidic platform development for organoid culture, several challenges remain. Standardization of culture protocols, scalability of microfluidic systems, integration of multiple organoid types, and long-term functionality of vascular networks are among the key areas that require further exploration. Addressing these challenges will contribute to the wider adoption of microfluidic platforms in the development of organoids for clinical applications.

In summary, the development of microfluidic platforms for organoid growth and vascularization represents a transformative approach in the field of regenerative medicine and disease modeling. These platforms provide precise control over the cellular microenvironment, enable the integration of vascular networks, and offer physiologically relevant models for studying human biology and disease. Continued research and innovation in this area have the potential to revolutionize personalized medicine, drug discovery, and tissue engineering, ultimately improving patient outcomes.

II. Organoid Culture and Challenges

Organoid culture involves the growth and maturation of three-dimensional (3D) structures that mimic the architecture and functionality of organs. While traditional culture methods have been successful in generating organoids, they often lack the ability to fully replicate the native tissue microenvironment, limiting their functionality and translational potential. Microfluidic platforms have emerged as a promising approach to address these limitations, offering precise control over the cellular microenvironment and the potential for vascular network integration. However, several challenges need to be overcome to optimize organoid culture using microfluidic platforms.

A. Recapitulating the Native Tissue Microenvironment:

One of the primary challenges in organoid culture is the accurate recapitulation of the native tissue microenvironment. Tissues are complex and dynamic, comprising various cell types, extracellular matrix components, and physiological cues. Replicating these factors in a controlled and reproducible manner is essential for generating functional and representative organoids. Microfluidic platforms provide the capability to precisely control parameters such as mechanical forces, oxygen gradients, nutrient supply, and waste removal, allowing for the customization of culture conditions to better mimic the native tissue microenvironment.

B. Vascularization of Organoids:

Vascularization is a critical aspect of organoid culture as it enables efficient nutrient and oxygen exchange and waste removal, supporting the growth and functionality of larger and more complex organoids. However, integrating functional vascular networks within organoids remains a significant challenge. Microfluidic platforms offer opportunities for the development of perfusable microchannels, the incorporation of endothelial cells, and the use of biomimetic scaffolds to facilitate the formation of vascular networks within organoids. Achieving long-term functionality and stability of these vascular networks is crucial for the successful culture of more physiologically relevant organoids.

C. Standardization of Culture Protocols:

The lack of standardized protocols for organoid culture represents a significant hurdle in the field. Currently, organoid culture methods can vary significantly between laboratories, making it challenging to compare and reproduce results. Standardization of culture protocols, including cell types, growth factors, culture medium compositions, and culture duration, is essential for establishing robust and reproducible organoid culture systems. Microfluidic platforms provide an opportunity to develop standardized protocols by providing controlled and consistent culture conditions, leading to more reliable and reproducible results.

D. Scalability and High-Throughput Screening:

As the field of organoids progresses towards clinical applications, scalability and highthroughput screening become crucial. Traditional organoid culture methods often lack scalability and struggle to generate large quantities of organoids. Microfluidic platforms offer opportunities for scalable organoid production by leveraging the advantages of microscale fluid dynamics and automation. Additionally, microfluidic platforms can facilitate high-throughput screening of organoids, enabling rapid and efficient testing of drug candidates and personalized medicine approaches.

E. Integration of Multiple Organoid Types:

In many cases, diseases or physiological processes involve the interaction of multiple organs. To better model such complex systems, it is essential to integrate multiple organoid types within a single culture system. This integration presents challenges in terms of compatibility, communication between organoids, and maintaining the functionality of each organoid. Microfluidic platforms can provide a means to spatially and temporally control the growth and interaction of multiple organoids, allowing for the creation of more comprehensive and physiologically relevant models.

III. Microfluidic Platforms for Organoid Culture

Microfluidic platforms have emerged as powerful tools for organoid culture, offering precise control over the cellular microenvironment and enabling the development of more physiologically relevant and functional organoids. These platforms provide unique advantages compared to traditional culture methods, allowing for the recapitulation of native tissue microenvironments, integration of vascular networks, and scalability for high-throughput screening. Here, we discuss the key features and advancements in microfluidic platforms for organoid culture.

A. Control of the Cellular Microenvironment:

Microfluidic platforms enable precise control over various factors that influence organoid growth and maturation. These platforms can regulate mechanical cues, such as shear stress and substrate stiffness, to mimic the physical forces experienced by cells in native tissues. The platforms also allow for the establishment of oxygen gradients within the organoids, which is crucial for supporting cell viability and differentiation. Furthermore, microfluidic systems can deliver nutrients and remove waste products efficiently, enhancing organoid growth and functionality.

B. Vascular Network Integration:

Vascularization is a critical aspect of organoid culture, and microfluidic platforms offer unique strategies for integrating functional vascular networks within organoids. These platforms can incorporate perfusable microchannels that mimic blood vessels, allowing for the flow of nutrients and oxygen to the organoid. Endothelial cells can be co-cultured within the microchannels, promoting the formation of endothelial-lined vessels. Additionally, biomimetic scaffolds can be designed to support the growth and organization of vascular networks within the organoids. The integration of vascular networks enhances organoid functionality, maturation, and long-term viability.

C. Customization and Personalization:

Microfluidic platforms provide a high degree of customization and personalization for organoid culture. By modulating the flow rates, composition of culture medium, and biochemical cues, the microenvironment can be tailored to specific organoid types or disease models. Patient-derived cells can be incorporated into the microfluidic platforms, allowing for the development of personalized organoid models that recapitulate the genetic and cellular characteristics of individual patients. This customization and personalization contribute to more accurate disease modeling, drug screening, and personalized medicine approaches.

D. High-throughput Screening and Automation:

Microfluidic platforms enable high-throughput screening of organoids, accelerating drug discovery efforts. The miniaturized and automated nature of microfluidic systems allows for the testing of multiple drugs or compounds simultaneously, reducing costs and time associated with traditional screening methods. The integration of microfluidic platforms with imaging and analysis techniques further enhances the capabilities for high-throughput screening, enabling the assessment of organoid morphology, functionality, and response to drugs in a rapid and efficient manner.

E. Organoid-on-a-Chip Systems:

Recent advancements have led to the development of organoid-on-a-chip systems, where multiple organoids or tissue types are integrated within a single microfluidic platform. These systems aim to replicate the interactions and crosstalk between different organs, providing a more comprehensive and physiologically relevant model of human physiology and disease. Organoid-on-a-chip platforms allow for the investigation of organ-organ interactions, drug metabolism, and toxicity testing, opening new avenues for personalized medicine and understanding complex biological processes.

IV. Microfluidic Vascularization Strategies

One of the key challenges in organoid culture is the successful integration of functional vascular networks within the 3D structures. Vascularization is crucial for supporting the growth,

maturation, and functionality of organoids by providing efficient nutrient and oxygen supply and waste removal. Microfluidic platforms offer innovative strategies for vascularization, enabling the formation of perfusable and functional vascular networks within organoids. Here, we discuss some of the microfluidic vascularization strategies employed in the development of organoid culture systems.

A. Perfusion-Based Microfluidic Systems:

Perfusion-based microfluidic systems involve the incorporation of perfusable microchannels within the organoid culture platform. These microchannels mimic blood vessels and allow for the flow of culture medium, nutrients, and oxygen to the organoid. The perfusion flow can be controlled to create physiologically relevant shear stresses and oxygen gradients, promoting the maturation and functionality of the organoids. Endothelial cells can be co-cultured within the microchannels, facilitating the formation of endothelial-lined vessels and enhancing the vascularization of the organoids.

B. Sacrificial Biofabrication:

Sacrificial biofabrication is a technique used to create vascular networks within organoids by employing sacrificial materials. In this approach, a sacrificial material, such as gelatin or alginate, is used to create a template of the desired vascular network within the organoid. Endothelial cells are then seeded onto the sacrificial template, allowing them to form vessel-like structures. Finally, the sacrificial material is selectively removed, leaving behind functional perfusable vessels within the organoid. Microfluidic platforms can facilitate the precise deposition and removal of sacrificial materials, enabling the formation of intricate vascular networks.

C. Biomimetic Scaffolds:

Biomimetic scaffolds provide a structural framework for the growth and organization of vascular networks within organoids. These scaffolds can be designed using microfluidic techniques to mimic the extracellular matrix (ECM) composition and architecture of native tissues. The scaffolds can be seeded with endothelial cells, which then undergo angiogenesis and form vessel-like structures. Microfluidic platforms allow for the precise fabrication of biomimetic scaffolds with controlled pore sizes, stiffness, and topographical features, promoting the formation of functional vascular networks within the organoids.

D. 3D Bioprinting:

3D bioprinting is a rapidly evolving technology that enables the precise deposition of cells, biomaterials, and growth factors in a layer-by-layer manner to create complex 3D structures. Microfluidic-based 3D bioprinting systems can be utilized to fabricate organoids with integrated vascular networks. Endothelial cells can be co-printed with other cell types to create perfusable vascular structures within the organoid. The ability to precisely control the spatial organization of cells and biomaterials in 3D bioprinting allows for the creation of intricate and functional vascular networks within the organoids.

E. Organ-on-a-Chip Systems:

Organ-on-a-chip systems combine microfluidic platforms with organoid culture to create more comprehensive models that mimic the interactions between different organs. In these systems,

multiple organoids representing different tissues or organs are interconnected through a perfusable microchannel network. This interconnected system allows for the exchange of nutrients, oxygen, and signaling molecules between the organoids, facilitating the development of functional vascular networks. Organ-on-a-chip systems provide a powerful tool for studying organ-organ interactions, disease modeling, and drug screening.

V. Advances and Applications

The development of microfluidic platforms for organoid growth and vascularization has yielded significant advances in the field of tissue engineering and regenerative medicine. These platforms offer precise control over the cellular microenvironment, enable the integration of vascular networks, and provide opportunities for customization and high-throughput screening. Here, we discuss some of the recent advances and applications of microfluidic platforms in organoid culture.

A. Disease Modeling:

Microfluidic platforms have revolutionized disease modeling by providing more physiologically relevant and personalized models of human organs and diseases. Organoids derived from patient cells can be cultured within microfluidic platforms, allowing for the study of disease mechanisms, drug responses, and personalized treatment approaches. These platforms enable the recapitulation of disease-specific microenvironments and the incorporation of multiple cell types to mimic the complexity of native tissues. Disease modeling using microfluidic organoid platforms has the potential to improve our understanding of disease progression, identify novel therapeutic targets, and facilitate precision medicine.

B. Drug Discovery and Screening:

Microfluidic platforms have proven to be valuable tools for drug discovery and screening. The integration of vascular networks within organoids enables the study of drug transport, metabolism, and toxicity in a more physiologically relevant context. Microfluidic systems can be used to perform high-throughput screening of drugs or compounds, allowing for rapid and cost-effective evaluation of their efficacy and safety. These platforms can also be employed to assess drug responses in personalized organoid models, facilitating the development of patient-specific treatment strategies.

C. Organoid Transplantation:

Microfluidic platforms have facilitated the development of functional and vascularized organoids that hold promise for transplantation and regenerative medicine applications. By integrating vascular networks within organoids, these platforms enhance the survival and maturation of transplanted organoids. The perfusable microchannels in the microfluidic systems enable efficient nutrient and oxygen delivery to the transplanted organoids, supporting their integration with host tissues. Microfluidic-based organoid transplantation strategies have the potential to address the shortage of donor organs and provide new options for organ replacement therapies.

D. Disease Mechanism Studies:

Microfluidic platforms have been instrumental in unraveling the underlying mechanisms of various diseases. These platforms allow for the precise control of microenvironmental factors, such as oxygen levels, shear stress, and biochemical cues, enabling the investigation of disease progression and cellular responses. Microfluidic organoid models have been used to study cancer invasion and metastasis, neurodegenerative diseases, developmental disorders, and infectious diseases. By providing a more physiologically relevant and controllable system, microfluidic platforms contribute to a deeper understanding of disease pathogenesis and the development of targeted therapeutic interventions.

E. Personalized Medicine:

Microfluidic platforms for organoid culture have the potential to revolutionize personalized medicine approaches. By incorporating patient-derived cells into the organoid models, these platforms enable the development of personalized disease models that capture the genetic and cellular heterogeneity of individual patients. Personalized organoid models can be used to predict individual drug responses, evaluate treatment efficacy, and guide clinical decision-making. Microfluidic-based platforms offer the scalability and automation required for the translation of personalized medicine into clinical practice.

VI. Future Directions and Conclusion

The development of microfluidic platforms for organoid growth and vascularization has opened up exciting possibilities for advancing tissue engineering, regenerative medicine, and disease modeling. However, there are still several challenges and future directions that need to be addressed in this field.

A. Vascular Network Complexity:

One of the key future directions is the development of microfluidic platforms that can replicate the complexity of native vascular networks. While current platforms have demonstrated the formation of perfusable vessels within organoids, there is a need for more intricate and hierarchical vascular structures. This would involve the integration of larger vessels, capillary networks, and the ability to mimic the dynamic nature of blood flow within these networks.

B. Integration of Immune Cells:

The immune system plays a crucial role in tissue development, homeostasis, and disease progression. Therefore, future microfluidic platforms should incorporate immune cells to create more physiologically relevant organoid models. This would allow for the study of immune responses, inflammation, and immune cell interactions within the context of organoid culture.

C. Long-Term Culture and Maturation:

Another important future direction is the improvement of long-term culture and maturation of organoids within microfluidic platforms. While current platforms can support the growth and functionality of organoids for a limited period, there is a need to enhance the long-term stability and maturation of these systems. This would involve optimizing culture conditions, providing

continuous nutrient and oxygen supply, and incorporating mechanical cues to mimic the native tissue microenvironment.

D. Integration of Multiple Organoids:

To better mimic the interactions between different organs, future microfluidic platforms should focus on the integration of multiple organoids into a single system. This would enable the study of organ-organ crosstalk, systemic drug responses, and disease modeling involving multiple organ systems. The development of organ-on-a-chip systems can further advance this integration and enable the creation of more comprehensive models of human physiology.

E. Translation to Clinical Applications:

For the widespread adoption of microfluidic-based organoid culture platforms, there is a need for further translation to clinical applications. This would involve addressing scalability, reproducibility, and regulatory considerations. Additionally, the development of automated systems and standardized protocols would facilitate the implementation of microfluidic platforms in clinical settings.

References

- 1. Maurya, A., Murallidharan, J. S., Sharma, A., & Agarwal, A. (2022, September 4). Microfluidics geometries involved in effective blood plasma separation. *Microfluidics and Nanofluidics*, 26(10). https://doi.org/10.1007/s10404-022-02578-4
- 2. Kong, T., Flanigan, S., Weinstein, M., Kalwa, U., Legner, C., & Pandey, S. (2017). A fast, reconfigurable flow switch for paper microfluidics based on selective wetting of folded paper actuator strips. *Lab on a Chip*, *17* (21), 3621-3633.
- 3. Curran, K., Colin, S., Baldas, L., & Davies, M. (2005, July 23). Liquid bridge instability applied to microfluidics. *Microfluidics and Nanofluidics*, 1(4), 336–345. https://doi.org/10.1007/s10404-005-0038-7
- Hong, L., & Pan, T. (2010, November 16). Surface microfluidics fabricated by photopatternable superhydrophobic nanocomposite. *Microfluidics and Nanofluidics*, 10(5), 991–997. <u>https://doi.org/10.1007/s10404-010-0728-7</u>
- 5. T. Kong, S. Flanigan, M. Weinstein, U. Kalwa, C. Legner, and S. Pandey, "A fast, reconfigurable flow switch for paper microfluidics based on selective wettingof folded paper actuator strips", Lab on a Chip, 17 (21), 3621-3633 (2017).
- 6.

A. Parashar, S. Pandey, "Plant-in-chip: Microfluidic system for studying root growth and pathogenic interactions in Arabidopsis", Applied Physics Letters, 98, 263703 (2011).

 J. Saldanha, A. Parashar, S. Pandey and J. Powell-Coffman, "Multi-parameter behavioral analyses provide insights to mechanisms of cyanide resistance in Caenorhabditis elegans", Toxicological Sciences 135(1):156-68. (2013).

- 8. Kuang, C., Qiao, R., & Wang, G. (2011, April 21). Ultrafast measurement of transient electroosmotic flow in microfluidics. *Microfluidics and Nanofluidics*, *11*(3), 353–358. https://doi.org/10.1007/s10404-011-0800-y
- Fair, R. B. (2007, March 8). Digital microfluidics: is a true lab-on-a-chip possible? *Microfluidics and Nanofluidics*, 3(3), 245–281. https://doi.org/10.1007/s10404-007-0161-8
- KNOBLAUCH, M., & PETERS, W. S. (2010, June 23). Münch, morphology, microfluidics - our structural problem with the phloem. *Plant, Cell & Environment*, nono. <u>https://doi.org/10.1111/j.1365-3040.2010.02177.x</u>
- 11. R. Lycke, A. Parashar, and S. Pandey, "Microfluidics-enabled method to identify modes of Caenorhabditis elegans paralysis in four anthelmintics", Biomicrofluidics 7, 064103 (2013).
- Zhang, J., & Catchmark, J. M. (2011, February 2). A catalytically powered electrokinetic lens: toward channelless microfluidics. *Microfluidics and Nanofluidics*, 10(5), 1147– 1151. https://doi.org/10.1007/s10404-010-0757-2
- Abadian, A., & Jafarabadi-Ashtiani, S. (2014, February 1). Paper-based digital microfluidics. *Microfluidics and Nanofluidics*, 16(5), 989–995. https://doi.org/10.1007/s10404-014-1345-7
- 14. Abadian, A., Sepehri Manesh, S., & Jafarabadi Ashtiani, S. (2017, March 24). Hybrid paper-based microfluidics: combination of paper-based analytical device (μPAD) and digital microfluidics (DMF) on a single substrate. *Microfluidics and Nanofluidics*, 21(4). <u>https://doi.org/10.1007/s10404-017-1899-2</u>
- 15. T. Kong, S. Flanigan, M. Weinstein, U. Kalwa, C. Legner, and S. Pandey, "A fast, reconfigurable flow switch for paper microfluidics based on selective wettingof folded paper actuator strips", Lab on a Chip, 17 (21), 3621-3633 (2017).
- Movahed, S., & Li, D. (2010, October 19). Microfluidics cell electroporation. *Microfluidics and Nanofluidics*, 10(4), 703–734. https://doi.org/10.1007/s10404-010-0716-y
- Lashkaripour, A., Silva, R., & Densmore, D. (2018, February 26). Desktop micromilled microfluidics. *Microfluidics and Nanofluidics*, 22(3). <u>https://doi.org/10.1007/s10404-018-2048-2</u>
- A. Parashar, S. Pandey, "Plant-in-chip: Microfluidic system for studying root growth and pathogenic interactions in Arabidopsis", Applied Physics Letters, 98, 263703 (2011).
- Lashkaripour, A., Silva, R., & Densmore, D. (2018, February 26). Desktop micromilled microfluidics. *Microfluidics and Nanofluidics*, 22(3). https://doi.org/10.1007/s10404-018-2048-2